Kwality Pharmaceuticals Limited — Q1FY27 earnings call summary

Filed 12 August 2026 · Official transcript

Oncology revenue expected INR100-110 crores in FY27; expansion adds 45-50% capacity
Biosimilar revenue target INR600-700 crores by FY29; Keytruda launch expected end CY28
Capex INR185-195 crores planned over FY27-FY29; funded by internal accruals
FY27 revenue guidance INR700+ crores; EBITDA margin 26-27%
EBITDA margin expected to reach ~30% by FY29 with revenue growth to INR1000 crores
Hormone plant commercializing Nov 2026; INR70-80 crores revenue in FY28, INR150-200 crores in FY29
FY30 revenue target INR1300-1500 crores; 35-40% generics, 25% oncology, 15-20% hormone, 15-30% biosimilars
Working capital improving; debtor days expected to reduce to 165-170 days